Indications for Concurrent Pradaxa (Dabigatran) and Plavix (Clopidogrel)
The primary indication for using dabigatran and clopidogrel together is in patients with atrial fibrillation who have undergone percutaneous coronary intervention (PCI), where this dual therapy strategy (without aspirin) has been shown to significantly reduce bleeding risk compared to traditional triple therapy while maintaining similar protection against thrombotic events.
Primary Clinical Scenario: Atrial Fibrillation + PCI
The combination of dabigatran and clopidogrel is specifically indicated when a patient has:
- Atrial fibrillation requiring oral anticoagulation (for stroke prevention)
- Recent acute coronary syndrome (ACS) or PCI with stenting (requiring antiplatelet therapy)
Evidence-Based Dosing Strategy
For most patients, the recommended approach is 1, 2:
- Dabigatran 150 mg twice daily + clopidogrel 75 mg daily (dual therapy, no aspirin)
- Dabigatran 110 mg twice daily + clopidogrel 75 mg daily for patients at higher bleeding risk
Dose selection based on bleeding risk 3, 1:
- Use dabigatran 110 mg twice daily if: age ≥80 years (≥70 in some regions), body weight <60 kg, or HAS-BLED score ≥3
- Use dabigatran 150 mg twice daily for younger patients with lower bleeding risk
Duration of Dual Therapy
After PCI in patients with atrial fibrillation 1:
- Early aspirin cessation (≤1 week post-PCI)
- Continue dabigatran + clopidogrel:
- Up to 6 months for uncomplicated PCI without high ischemic risk
- Up to 12 months for high ischemic risk (left main stent, multivessel PCI, complex anatomy)
- Then transition to dabigatran monotherapy for lifelong stroke prevention
High Ischemic Risk Features
Consider 12-month dual therapy duration if 1:
- Left main coronary artery stenting
- Proximal left anterior descending artery involvement
- Multivessel PCI
- Complex lesion characteristics
- Recent acute coronary syndrome
Key Clinical Distinctions
Why Clopidogrel (Not Other P2Y12 Inhibitors)?
Clopidogrel is strongly preferred over prasugrel or ticagrelor when combined with oral anticoagulation 3, 4:
- Lower bleeding risk compared to more potent P2Y12 inhibitors
- Prasugrel is not recommended in combination with anticoagulants due to 4-fold increased bleeding risk
- Ticagrelor may be considered only in very low bleeding risk/high thrombotic risk scenarios, but data remain limited
Why Omit Aspirin?
The RE-DUAL PCI trial demonstrated that dual therapy (dabigatran + clopidogrel without aspirin) is superior to triple therapy 2:
- 48% reduction in major/clinically relevant bleeding with dabigatran 110 mg dual therapy (HR 0.52)
- 28% reduction with dabigatran 150 mg dual therapy (HR 0.72)
- Non-inferior for preventing thrombotic events (MI, stroke, death, revascularization)
Important Clinical Caveats
Renal Function Considerations
Adjust dabigatran dosing based on creatinine clearance 5:
- CrCl 30-50 mL/min: Consider dabigatran 110 mg twice daily
- CrCl <30 mL/min: Dabigatran is contraindicated
- Bleeding reduction benefits maintained across all renal function categories
Age-Specific Considerations
In patients ≥75 years 6:
- Dabigatran 110 mg dual therapy shows clear bleeding benefit (HR 0.67)
- Dabigatran 150 mg dual therapy shows no bleeding benefit in elderly (HR 1.21)
- Therefore, use 110 mg dose in patients ≥75 years
Gastrointestinal Protection
Proton pump inhibitor is recommended for all patients on dual antithrombotic therapy 3, 1:
- Reduces GI bleeding risk by approximately 50%
- Continue throughout duration of combined therapy
What This Combination Does NOT Treat
Important: This is NOT indicated for 7:
- Stable coronary artery disease with atrial fibrillation (use anticoagulation alone after 1 year post-ACS)
- Venous thromboembolism treatment (different indication for dabigatran, typically without antiplatelet agents)
- Primary prevention in patients without both AF and recent coronary intervention
Stable CAD + Atrial Fibrillation
After 12 months post-ACS or PCI, patients with stable coronary disease and atrial fibrillation should receive 3:
- Oral anticoagulation monotherapy (dabigatran alone)
- No additional antiplatelet therapy - adding aspirin increases bleeding without reducing thrombotic events
Switching Considerations
Patients already on anticoagulation pre-PCI can safely switch to dabigatran dual therapy post-PCI 8:
- Bleeding benefits consistent regardless of prior anticoagulant use
- No need to continue warfarin if patient was on it pre-procedure
- Direct oral anticoagulants preferred over warfarin for lower bleeding risk